Product Details
SITAGLIPTIN 50 MG + DAPAGLIFLOZIN 5 MG
Introduction : Dapagliflozin 50mg & Sitagliptin 5mg tablet, work together to help lower blood sugar levels in individuals with T2DM.
Dapagliflozin increases urinary glucose excretion, reducing blood glucose levels.
Sitagliptin enhances insulin secretion and reduces glucagon levels after meals, which helps control blood sugar levels.
Dapagliflozin 50mg & Sitagliptin 5mg tablet typically prescribed as an adjunct to diet and exercise when lifestyle modifications alone are insufficient to control blood sugar levels in patients with T2DM.
It helps improve overall glycemic control and reduces the risk of diabetes-related complications.
Indication : Dapagliflozin 50mg & Sitagliptin 5mg tablet is commonly used for the management of type 2 diabetes mellitus (T2DM) to improve glycemic control and reduce the risk of diabetes-related complications.
It may be prescribed as an adjunct to diet and exercise in individuals whose diabetes is not adequately controlled with metformin alone or in combination with other antidiabetic agents.
Administration : The dosage of Dapagliflozin 5 mg + Sitagliptin 50 mg may vary based on individual patient factors such as kidney function, glycemic control, and response to treatment.
Typically, the medication is taken orally, with or without food, once or twice daily as prescribed by a healthcare professional.
Storage : Store the medication at room temperature, away from moisture, heat, and direct sunlight.
Mechanism of Action : Dapagliflozin 10 mg: Dapagliflozin is a sodium-glucose cotransporter 2 (SGLT2) inhibitor that helps lower blood sugar levels by inhibiting glucose reabsorption in the kidneys, leading to increased glucose excretion in urine.
Sitagliptin 100 mg: Sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor that works by inhibiting the enzyme DPP-4, which inactivates incretin hormones responsible for increasing insulin release and decreasing glucagon secretion.
Therapeutic : Anti Diabetic
Side Effects : Common side effects of this combination medication may include:
Genitourinary tract infections (such as urinary tract infections or genital yeast infections) due to increased glucose excretion in urine with dapagliflozin.
Hypoglycemia (low blood sugar) when used in combination with other antidiabetic agents.
Gastrointestinal disturbances such as diarrhea, nausea, vomiting, or abdominal discomfort, particularly with metformin.
Contraindications : Acute or chronic metabolic acidosis including diabetic ketoacidosis
Severe renal impairment
Avoid use of this drug during pregnancy and prescribe an alternative. Evidence has demonstrated fetal abnormalities or risks when used during pregnancy. Advise women of childbearing potential of fetal risk.
Safety Advice / Warnings : Avoid alcohol and tobaccco consumption while taking this medicnes
Hyperglycemia (high blood sugar) may occur if you do not take enough or skip a dose of your medicine, overeat or do not follow your meal plan, have a fever or infection, or do not exercise as much as usual. High blood sugar can be very serious and must be treated right away. It is important that you learn which symptoms you have in order to treat it quickly. Talk to your doctor about the best way to treat high blood sugar.
Dizziness, lightheadedness, or fainting may occur with this medicine. Drink plenty of water during exercise or in hot weather. Check with your doctor if you have severe nausea, vomiting, or diarrhea that does not stop. This may cause you to lose too much water.
References : Product Information: Disit 50MG oral tablet, sitagliptin hydrochloride monohydrate 50MG oral tablet. Laboratorios Alter, SA (per AEMPS;Spain), C/Mateo Inurria 30, 28036 Madrid, Spain, 2019.
Product Information: ZITUVIO oral tablets, sitagliptin oral tablets. Zydus Pharmacuticals (USA) Inc (per FDA), Pennington, NJ, 2023.
Product Information: FORXIGA(R) oral tablets, dapagliflozin oral tablets. AstraZeneca Pharmaceuticals LP (per manufacturer), Wilmington, DE, 2021.
Dandona P, Mathieu C, Phillip M, et al: Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial. Lancet Diabetes Endocrinol 2017; 5(11):864-876.